Michael Panaccio

Michael Panaccio is the founder of Starfish Ventures Pty Ltd., founded in 2001, where the title held is Investment Principal.
Current jobs include Chairman at Cylite Pty Ltd., Director at MetaCDN Pty Ltd., Director at Hayylo Platforms Pty Ltd., Director at Margin-Clear Pty Ltd., and Director at Marp Therapeutics Pty Ltd. Former jobs include Chairman at Australian Biotechnology & Healthcare Fund No.
3 Ltd., Non-Executive Chairman at dorsaVi Ltd. from 2022 to 2024, Chairman at MuriGen Pty Ltd., Director at Protagonist Pty Ltd., Director at Sirtex Medical Pty Ltd., Director at Australian Investment Council Ltd., Director at Finisar Australia Pty Ltd., Independent Non-Executive Director at ImpediMed Ltd. from 2007 to 2016, Non-Executive Director at Mimetica Pty Ltd., Director at Protagonist Therapeutics, Inc., Director at Ofidium Pty Ltd., Director at EnerNOC Pty Ltd., Non-Executive Director at TeeleOstin Ltd., Director at Armaron Bio Ltd., Director at ANU Enterprise Pty Ltd., Independent Non-Executive Director at ReNerve Ltd. from 2018 to 2025, Investment Manager at JAFCO Investment (Asia Pacific) Ltd., Head-Molecular Biology Department at Attwood Victorian Institute of Animal Science, and Head-Molecular Biology Department at Victorian Institute of Animal Sciences.
Education includes undergraduate and doctorate degrees from the University of Melbourne and an MBA from RMIT University.